title: Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.
abstract: Cancer cells evolve from normal cells throughout life and are usually recognized by our immune system and destroyed, a process called immunosurveillance. Unfortunately, in some instances cancer cells paralyze our immune system, resulting in outgrowth and spreading of the tumor. Understanding the complexity of immunomodulation by tumors is important for the development of therapeutical strategies. Nowadays, various approaches have been developed to enhance anti-tumor immune responses and abrogate the immune dampening effect of the tumor and its surrounding environment, including dendritic cell-based vaccines, therapies to counteract myeloid derived suppressor cell function within the tumor and antagonists of inhibitory signaling pathways to overcome 'immune checkpoints'. The challenge is now to find the right combination of immune based therapies to fully restore immune function and provide a more efficacious and enduring anti-tumor response.
authors.affiliation: Radboud Institute for Molecular Life Sciences, Radboudumc, Department of Tumorimmunology, Geert Grooteplein 26, 6525GA Nijmegen, The Netherlands.
authors.forename: Angela
authors.initials: A
authors.lastname: Vasaturo
authors.affiliation: Radboud Institute for Molecular Life Sciences, Radboudumc, Department of Tumorimmunology, Geert Grooteplein 26, 6525GA Nijmegen, The Netherlands.
authors.forename: Martijn
authors.initials: M
authors.lastname: Verdoes
authors.affiliation: Radboud Institute for Molecular Life Sciences, Radboudumc, Department of Tumorimmunology, Geert Grooteplein 26, 6525GA Nijmegen, The Netherlands.
authors.forename: Jolanda
authors.initials: J
authors.lastname: de Vries
authors.affiliation: Radboud Institute for Molecular Life Sciences, Radboudumc, Department of Tumorimmunology, Geert Grooteplein 26, 6525GA Nijmegen, The Netherlands.
authors.forename: Ruurd
authors.initials: R
authors.lastname: Torensma
authors.affiliation: Radboud Institute for Molecular Life Sciences, Radboudumc, Department of Tumorimmunology, Geert Grooteplein 26, 6525GA Nijmegen, The Netherlands. Electronic address: Carl.Figdor@radboudumc.nl.
authors.forename: Carl G
authors.initials: CG
authors.lastname: Figdor
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D056747:Immunomodulation; D007167:Immunotherapy; D015166:Monitoring, Immunologic; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D059016:Tumor Microenvironment / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines
keywords: Cancer; Dendritic cell vaccination; Immunosuppression; Immunotherapy; Tumor immunology; Tumor microenvironment